Table 5.

Results of base-case mixed-treatment comparison analysis

Reference	Comparator	All strokes	Ischemic stroke	Myocardial infarction	Overall mortality	Major bleeding	Intracranial hemorrhage
Warfarin	ASA + C	1.44	1.87	1.05	1.02	1.16	1.32
		(1.15–1.8)	(1.45–2.42)	(0.75–1.47)	(0.88–1.18)	(0.92–1.45)	(0.81–2.19)
	Aspirin	1.93	2.68	1.22	1.05	0.77	0.64
		(1.55–2.41)	(2.08–3.47)	(0.88–1.68)	(0.91–1.21)	(0.61–0.98)	(0.39–1.04)
	Placebo	2.39	3.75	1.96	1.22	0.57	0.22
		(1.77–3.24)	(2.64–5.33)	(0.86–4.44)	(0.94–1.57)	(0.32–1)	(0.07–0.65)
	Apixaban	0.82	0.97	0.87	0.89	0.71	0.42
		(0.69–0.97)	(0.79–1.19)	(0.67–1.13)	(0.8–0.98)	(0.62–0.81)	(0.31–0.57)
	Dabigatran 110	0.92	1.14	1.23	0.92	0.82	0.3
		(0.75–1.14)	(0.9–1.44)	(0.92–1.65)	(0.81–1.04)	(0.71–0.94)	(0.19–0.45)
	Dabigatran 150	0.65	0.76	1.2	0.89	0.94	0.41
		(0.52–0.82)	(0.59–0.99)	(0.9–1.61)	(0.79–1.01)	(0.82–1.08)	(0.28–0.6)
	Rivaroxaban	0.85	0.95	0.82	0.94	1.03	0.65
		(0.7–1.03)	(0.76–1.18)	(0.64–1.07)	(0.84–1.05)	(0.9–1.19)	(0.46–0.91)
	Edoxaban HD	0.89	1.01	0.94	0.92	0.8	0.46
		(0.76–1.04)	(0.84–1.21)	(0.74–1.18)	(0.84–1.02)	(0.71–0.91)	(0.34–0.62)
	Edoxaban LD	1.12	1.4	1.17	0.87	0.48	0.3
		(0.96–1.3)	(1.18–1.65)	(0.94–1.46)	(0.78–0.96)	(0.41–0.56)	(0.21–0.43)
ASA + C	Aspirin	1.34	1.44	1.16	1.03	0.67	0.48
		(1.17–1.55)	(1.23–1.68)	(0.91–1.48)	(0.94–1.13)	(0.56–0.8)	(0.32–0.72)
	Placebo	1.66	2.01	1.87	1.2	0.49	0.17
		(1.29–2.15)	(1.5–2.69)	(0.84–4.07)	(0.95–1.51)	(0.28–0.85)	(0.05–0.47)
	Apixaban	0.57	0.52	0.83	0.87	0.61	0.32
		(0.44–0.73)	(0.39–0.69)	(0.57–1.21)	(0.74–1.03)	(0.48–0.79)	(0.18–0.54)
	Dabigatran 110	0.64	0.61	1.17	0.90	0.71	0.22
		(0.47–0.87)	(0.43–0.86)	(0.76–1.82)	(0.74–1.1)	(0.54–0.93)	(0.11–0.43)
	Dabigatran 150	0.45	0.41	1.15	0.88	0.82	0.31
		(0.33–0.62)	(0.28–0.59)	(0.74–1.77)	(0.72–1.07)	(0.63–1.06)	(0.17–0.58)
	Rivaroxaban	0.59	0.51	0.78	0.92	0.9	0.49
		(0.44–0.8)	(0.36–0.71)	(0.51–1.19)	(0.77–1.11)	(0.68–1.17)	(0.27–0.9)
	Edoxaban HD	0.62	0.54	0.89	0.91	0.7	0.35
		(0.47–0.81)	(0.39–0.74)	(0.6–1.34)	(0.76–1.09)	(0.53–0.9)	(0.19–0.62)
	Edoxaban LD	0.78	0.75	1.12	0.85	0.41	0.23
		(0.59–1.02)	(0.55–1.02)	(0.75–1.66)	(0.71–1.02)	(0.32–0.54)	(0.12–0.42)
ASA	Placebo	1.24	1.4	1.62	1.16	0.74	0.35
		(1–1.54)	(1.09–1.8)	(0.75–3.36)	(0.94–1.44)	(0.42–1.25)	(0.11–0.91)
	Apixaban	0.42	0.36	0.72	0.85	0.92	0.66
		(0.33–0.54)	(0.28–0.48)	(0.51–1.01)	(0.73–0.99)	(0.71–1.18)	(0.4–1.09)
	Dabigatran 110	0.48	0.42	1.01	0.88	1.06	0.46
		(0.35–0.64)	(0.3–0.6)	(0.66–1.55)	(0.72–1.06)	(0.8–1.4)	(0.24–0.88)
	Dabigatran 150	0.34	0.28	0.99	0.85	1.22	0.65
		(0.25–0.46)	(0.2–0.41)	(0.65–1.51)	(0.7–1.03)	(0.93–1.61)	(0.35–1.19)
	Rivaroxaban	0.44	0.35	0.68	0.9	1.34	1.03
		(0.33–0.59)	(0.25–0.5)	(0.45–1.02)	(0.75–1.08)	(1.02–1.76)	(0.57–1.85)
	Edoxaban HD	0.46	0.38	0.77	0.88	1.04	0.72
		(0.35–0.6)	(0.28–0.51)	(0.52–1.14)	(0.74–1.05)	(0.79–1.36)	(0.41–1.28)
	Edoxaban LD	0.58	0.52	0.96	0.83	0.62	0.48
		(0.44–0.76)	(0.38–0.71)	(0.65–1.42)	(0.69–0.98)	(0.47–0.82)	(0.26–0.86)
Placebo	Apixaban	0.34	0.26	0.44	0.73	1.24	1.9
		(0.25–0.47)	(0.18–0.37)	(0.2–1.03)	(0.56–0.95)	(0.7–2.26)	(0.64–6.49)
	Dabigatran 110	0.39	0.3	0.62	0.75	1.43	1.33
		(0.27–0.55)	(0.2–0.46)	(0.27–1.49)	(0.57–1)	(0.8–2.62)	(0.42–4.86)
	Dabigatran 150	0.27	0.2	0.61	0.73	1.66	1.87
		(0.19–0.4)	(0.13–0.31)	(0.26–1.47)	(0.55–0.97)	(0.93–3.02)	(0.59–6.69)
	Rivaroxaban	0.36	0.25	0.42	0.77	1.81	2.96
		(0.25–0.51)	(0.17–0.38)	(0.18–1)	(0.58–1.02)	(1.02–3.32)	(0.95–10.4)
	Edoxaban HD	0.37	0.27	0.48	0.76	1.41	2.08
		(0.26–0.52)	(0.18–0.4)	(0.21–1.12)	(0.58–1)	(0.79–2.57)	(0.68–7.3)
	Edoxaban LD	0.47	0.37	0.60	0.71	0.84	1.37
		(0.33–0.66)	(0.25–0.55)	(0.26–1.4)	(0.54–0.93)	(0.47–1.54)	(0.44–4.86)
Apixaban	Dabigatran 110	1.13	1.17	1.41	1.03	1.16	0.7
		(0.86–1.47)	(0.86–1.6)	(0.96–2.07)	(0.88–1.22)	(0.95–1.41)	(0.41–1.18)
	Dabigatran 150	0.8	0.78	1.38	1	1.33	0.98
		(0.6–1.06)	(0.56–1.09)	(0.95–2.02)	(0.85–1.19)	(1.1–1.62)	(0.6–1.58)
	Rivaroxaban	1.04	0.97	0.95	1.06	1.46	1.55
		(0.8–1.35)	(0.72–1.32)	(0.65–1.36)	(0.91–1.23)	(1.2–1.78)	(0.98–2.46)
	Edoxaban HD	1.09	1.04	1.08	1.04	1.13	1.1
		(0.86–1.37)	(0.79–1.36)	(0.76–1.52)	(0.9–1.2)	(0.94–1.37)	(0.71–1.68)
	Edoxaban LD	1.37	1.44	1.35	0.97	0.68	0.72
		(1.09–1.72)	(1.11–1.88)	(0.96–1.88)	(0.84–1.12)	(0.55–0.83)	(0.45–1.14)
Dabigatran 110	Dabigatran 150	0.71	0.67	0.98	0.97	1.15	1.4
		(0.56–0.89)	(0.52–0.86)	(0.74–1.3)	(0.85–1.11)	(1–1.33)	(0.85–2.32)
	Rivaroxaban	0.92	0.83	0.67	1.02	1.27	2.21
		(0.69–1.22)	(0.6–1.15)	(0.45–0.99)	(0.86–1.22)	(1.04–1.55)	(1.29–3.85)
	Edoxaban HD	0.97	0.89	0.76	1.01	0.98	1.56
		(0.74–1.25)	(0.66–1.19)	(0.53–1.11)	(0.86–1.18)	(0.81–1.19)	(0.93–2.67)
	Edoxaban LD	1.21	1.23	0.96	0.94	0.59	1.02
		(0.94–1.56)	(0.92–1.64)	(0.66–1.37)	(0.8–1.11)	(0.48–0.72)	(0.59–1.8)
Dabigatran 150	Rivaroxaban	1.31	1.24	0.68	1.05	1.1	1.58
		(0.97–1.77)	(0.88–1.75)	(0.46–1.01)	(0.89–1.25)	(0.9–1.33)	(0.96–2.64)
	Edoxaban HD	1.37	1.32	0.78	1.04	0.85	1.12
		(1.04–1.81)	(0.96–1.82)	(0.54–1.13)	(0.88–1.22)	(0.71–1.02)	(0.69–1.83)
	Edoxaban LD	1.72	1.83	0.97	0.97	0.51	0.73
		(1.31–2.26)	(1.35–2.5)	(0.68–1.4)	(0.82–1.14)	(0.41–0.62)	(0.44–1.23)
Rivaroxaban	Edoxaban HD	1.05	1.07	1.14	0.98	0.78	0.71
		(0.81–1.35)	(0.8–1.42)	(0.8–1.62)	(0.85–1.14)	(0.64–0.94)	(0.45–1.11)
	Edoxaban LD	1.31	1.48	1.42	0.92	0.46	0.46
		(1.03–1.68)	(1.12–1.95)	(1.01–2)	(0.79–1.07)	(0.38–0.57)	(0.29–0.75)
Edoxaban HD	Edoxaban LD	1.26	1.38	1.25	0.94	0.60	0.66
		(1.08–1.47)	(1.17–1.64)	(0.99–1.57)	(0.85–1.03)	(0.51–0.7)	(0.44–0.97)

Notes: Results presented as rate ratios, with 95% credible intervals in parentheses below. Significant results are in bold.

Abbreviations: ASA, acetylsalicylic acid (aspirin); C, clopidogrel; HD, high dose; LD, low dose.